Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Protection: Should Third Parties Be Able To Request PTO Director Review Of PTAB Decisions?

Executive Summary

Agency asks stakeholders to weigh in on the process for director review of decisions by the Patent Trial and Appeal Board. PTO questions whether review should be limited to final written decisions and if the precedential opinion process should remain in effect.

You may also be interested in...



Will USPTO’s PTAB Undergo A Makeover? Senators Push Reform Bill, Patent Office Tweaks Policy

Parallel district court litigation would no longer be factor in deciding whether to institute PTAB review of patents under Senate bill. BIO favors PTO discretion, would like claim amendments to be addressed.

US Supreme Court Gives PTO Director Chance To Impact Outcome Of Patent Disputes

High court finds PTAB judges were unconstitutionally appointed; ruling is unlikely to benefit one party over another in inter partes review proceedings, attorneys say, but that could depend on the director. PTO is expected to provide guidance on how and when to request review of Patent Trial and Appeal Board decisions.

Social Media Data Gains Prominence In Patient-Focused Drug Development

FDA guidances have provided ‘major step forward’ for use of social media data, Roche researcher notes. Agency staffer offers checklist for collecting patient experience data in this realm.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel